Human trials in place for new asthma drug
A new drug for curing asthma patients, RPL554, which faced trials at the Centre for Human Drug Research (CHDR) in the Netherlands on more than 60 people in 2008, is now moving to the stage of further trials during 2009.
This drug, which is considered by many as nothing but a wonder drug, is likely to prove its worth in treating more than 1.5 million people in the United States alone suffering from asthma and hay fever. It is expected that drug will reach the market in the next three to four years after evaluating its safety and efficacy.
From News-Medical.Net:
Current treatments for asthma and hay fever sufferers are beta-agonists, which open up the airways, and inhaled steroids, which dampen down the inflammation that causes irritation – they are either taken together or singly.
But they have serious side effects, including possible harm to the cardiovascular system and the ’shakes’ reported by many patients from excess use.
Experts say little progress has been made recently with alternative, effective and practical treatment options for a wide range of people with asthma and hay fever and by combining anti-inflammatory properties and the ability to overcome airway narrowing in a single long-lasting dose via the nose, RPL554 could offer real hope of a significant breakthrough.
It was remarked by some researchers that this once-a-day asthma treatment option will be nothing less than a first-line therapy for treating patients suffering from hay fever and asthma. The discovery of this drug would mean that asthmatic patients will now require only a single needle puff from their “lifesaving” inhalers to stop the symptoms.
Tags: asthma, hay fever, inhaled steroids, RPL554, Steroids, treating asthma
Recent Comments